SH2B1

Across TCGA pan-cancer cohorts, SH2B1 RNA differs between tumor and matched normal tissue in 9 of 18 cancer types tested, making tumor–normal expression one of SH2B1’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where SH2B1 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types SH2B1 is over-expressed in tumor, although a few such as THCA and UCEC show the opposite, repressed pattern.

LIHC, THCA, and KIRP are the cancer types where SH2B1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SH2B1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	Female	II,III,IV	+1.450	<.001	8	view →
THCA	All	All	−0.232	.002	8	view →
KIRP	Female	All	+0.578	.024	6	view →
CHOL	Female	All	+2.190	<.001	5	view →
UCEC	All	II,III,IV	−0.543	.004	4	view →
BRCA	Female	All	−0.293	.001	4	view →
STAD	Male	II,III,IV	+0.700	.015	2	view →
READ	All	All	−0.485	.007	2	view →
LUAD	Male	All	−0.358	.028	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 9 strongest of 9 lineages.

SH2B1–LIHC

Open the LIHC breakdown →